Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia (AML)

被引：7
|
作者：
Stone, Richard M. [1 ]
DeAngelo, Daniel J. [1 ]
Galinsky, Ilene [1 ]
Kokulis, Caroline [1 ]
Stewart, Jeremy M. [1 ]
McGinnis, Michael [1 ]
Werner, Lillian [2 ]
Letai, Anthony G. [1 ]
Konopleva, Marina Y. [3 ]
Luskin, Marlise [1 ]
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-124966
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3908
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Maximal Tolerated Dose of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction in Previously Untreated Adults with Acute Myeloid Leukemia (AML)
    Stone, Richard M.
    DeAngelo, Daniel J.
    Letai, Anthony G.
    Stewart, Jeremy M.
    McGinnis, Michael
    Brown, Francis
    Fell, Geoffrey
    Flammand, Yael
    Konopleva, Marina
    Garcia, Jacqueline S.
    Luskin, Marlise R.
    BLOOD, 2020, 136
  • [2] Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia
    Sweet, Kendra
    Komrokji, Rami
    Padron, Eric
    Cubitt, Christopher L.
    Turner, Joel G.
    Zhou, Junmin
    List, Alan F.
    Sallman, David A.
    Dawson, Jana L.
    Sullivan, Daniel M.
    Chavez, Julio
    Shah, Bijal D.
    Lancet, Jeffrey E.
    CLINICAL CANCER RESEARCH, 2020, 26 (01) : 54 - 60
  • [3] Clinical activity of Genasense™ (GNS, oblimersen sodium), a pro-apoptotic to Bcl-2 oligonucleotide, in combination with daunorubicin and cytarabine:: A phase I study in previously untreated elderly acute myeloid leukemia (AML).
    Marcucci, G
    Stock, W
    Zwiebel, JA
    Cataland, SR
    Dai, G
    Moran, M
    Lucas, D
    Liu, S
    Klisovic, MI
    Kefauver, C
    Green, M
    Chan, KK
    Frankel, SR
    Grever, MR
    Byrd, JC
    BLOOD, 2003, 102 (11) : 385A - 385A
  • [4] CYTARABINE PLUS IDARUBICIN OR DAUNORUBICIN AS INDUCTION AND CONSOLIDATION THERAPY FOR PREVIOUSLY UNTREATED ADULT PATIENTS WITH ACUTE MYELOID-LEUKEMIA
    WIERNIK, PH
    BANKS, PLC
    CASE, DC
    ARLIN, ZA
    PERIMAN, PO
    TODD, MB
    RITCH, PS
    ENCK, RE
    WEITBERG, AB
    BLOOD, 1992, 79 (02) : 313 - 319
  • [5] Pharmacologie and biologic assessment of Genasense™ (GNS, oblimersen sodium), a pro-apoptotic to Bcl-2 oligonucleotide, in combination with daunorubicin and cytarabine:: A phase I study in previously untreated elderly acute myeloid leukemia (AML).
    Marcucci, G
    Dai, GW
    Klisovic, MI
    Shen, TS
    Liu, SJ
    Sher, DA
    Lucas, D
    Whitman, SP
    Vukosavljevic, T
    Zwiebel, JA
    Frankel, SR
    Grever, MR
    Stock, W
    Chan, KK
    Byrd, JC
    BLOOD, 2003, 102 (11) : 874A - 874A
  • [6] Phase I dose escalating trial of bortezomib (Veleade®) in combination with idarubicin and cytarabine in patients with acute myeloid leukemia.
    Attar, EC
    DeAngelo, DJ
    Ballen, KK
    Learner, E
    Trehu, EG
    Schenkein, DP
    Levine, JD
    Stone, RM
    Amrein, PC
    BLOOD, 2004, 104 (11) : 498A - 499A
  • [7] Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia
    Wei, Hui
    Wang, Ying
    Gale, Robert Peter
    Lin, Dong
    Zhou, Chunlin
    Liu, Bingcheng
    Qiu, Shaowei
    Gu, Runxia
    Li, Yan
    Zhao, Xingli
    Wei, Shuning
    Gong, Benfa
    Liu, Kaiqi
    Gong, Xiaoyuan
    Liu, Yuntao
    Zhang, Guangji
    Song, Zhen
    Wang, Yang
    Li, Wei
    Mi, Yingchang
    Wang, Jianxiang
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 3154 - 3161
  • [8] A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia
    Lancet, Jeffrey E.
    Baer, Maria R.
    Duran, George E.
    List, Alan F.
    Fielding, Robert
    Marcelletti, John F.
    Multani, Pratik S.
    Sikic, Branimir I.
    LEUKEMIA RESEARCH, 2009, 33 (08) : 1055 - 1061
  • [9] Venetoclax Combined with Daunorubicin and Cytarabine (2+6) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial
    Suo, Xiaohui
    Wang, Dongmei
    Zheng, Fang
    Zhang, Suping
    Zhang, Congcong
    Li, Yinling
    Shi, Rui
    Wu, Yan
    Yang, Sisi
    Zhao, Liyun
    Jiao, Zongjiu
    Liu, Jie
    Zhang, Ling
    Li, Ling
    Zhang, Zhihua
    Lu, Xinxiao
    Yuan, Linyu
    Gao, Sifeng
    Zhang, Jilei
    Zhao, Xingli
    Bai, Guanchen
    Mi, Yingchang
    Liu, Kaiqi
    BLOOD, 2023, 142
  • [10] Venetoclax combined with daunorubicin and cytarabine (2+6) in acute myeloid leukemia: Updated results of a phase II trial
    Suo, Xiaohui
    Fang, Zheng
    Wang, Dongmei
    Zhao, Liyun
    Liu, Jie
    Li, Hong
    Ma, Xiaojun
    Zhang, Congcong
    Zhao, Xuemei
    Shi, Rui
    Wu, Yan
    Jiao, Zongjiu
    Song, Jiaojie
    Zhang, Ling
    Li, Ling
    Zhang, Suping
    Lu, Xinxiao
    Yuan, Linyu
    Gao, Sifeng
    Zhang, Jilei
    Liu, Kaiqi
    Zhao, Xingli
    Bai, Guanchen
    Mi, Yingchang
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (04)
12345